Olive oil, 4g + omega-3-carboxylic acids, 2g + omega-3-carboxylic acids, 4g

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypertriglyceridemia

Conditions

Hypertriglyceridemia, Cardiovascular Disease

Trial Timeline

Aug 1, 2011 โ†’ Jun 1, 2012

About Olive oil, 4g + omega-3-carboxylic acids, 2g + omega-3-carboxylic acids, 4g

Olive oil, 4g + omega-3-carboxylic acids, 2g + omega-3-carboxylic acids, 4g is a phase 3 stage product being developed by AstraZeneca for Hypertriglyceridemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01408303. Target conditions include Hypertriglyceridemia, Cardiovascular Disease.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01408303Phase 3Completed

Competing Products

20 competing products in Hypertriglyceridemia

See all competitors